Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7759
- TODAY'S CHANGE (%)0.0060 (0.7793%)
- Bid / Lots0.7600/ 2
- Ask / Lots0.7800/ 145
- Open / Previous Close0.7750 / 0.7699
- Day Range
- 52 Week Range
- Volume571,591
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 9441 | 0.7699 |
| 09:36 ET | 1979 | 0.756 |
| 09:38 ET | 100 | 0.779 |
| 09:39 ET | 100 | 0.779 |
| 09:41 ET | 200 | 0.779 |
| 09:56 ET | 100 | 0.756 |
| 09:59 ET | 100 | 0.7765 |
| 10:03 ET | 100 | 0.76705 |
| 10:06 ET | 600 | 0.76705 |
| 10:08 ET | 200 | 0.7565 |
| 10:12 ET | 200 | 0.7677 |
| 10:17 ET | 100 | 0.7778 |
| 10:19 ET | 192 | 0.7577 |
| 10:21 ET | 200 | 0.7578 |
| 10:26 ET | 200 | 0.7676 |
| 10:28 ET | 300 | 0.777 |
| 10:30 ET | 300 | 0.7581 |
| 10:35 ET | 200 | 0.7582 |
| 10:37 ET | 700 | 0.777299 |
| 10:39 ET | 100 | 0.7687 |
| 10:42 ET | 200 | 0.773025 |
| 10:48 ET | 600 | 0.7646 |
| 10:50 ET | 100 | 0.7646 |
| 10:53 ET | 100 | 0.7647 |
| 10:55 ET | 392 | 0.7673 |
| 10:57 ET | 1640 | 0.7738 |
| 11:00 ET | 100 | 0.7738 |
| 11:02 ET | 422 | 0.7697 |
| 11:04 ET | 3347 | 0.7696 |
| 11:08 ET | 100 | 0.7737 |
| 11:09 ET | 1123 | 0.7724 |
| 11:11 ET | 700 | 0.7724 |
| 11:13 ET | 600 | 0.77235 |
| 11:15 ET | 100 | 0.7725 |
| 11:18 ET | 2760 | 0.77315 |
| 11:20 ET | 600 | 0.773 |
| 11:24 ET | 800 | 0.773 |
| 11:26 ET | 1115 | 0.773 |
| 11:27 ET | 14127 | 0.762 |
| 11:29 ET | 3450 | 0.7645 |
| 11:31 ET | 2775 | 0.7645 |
| 11:38 ET | 1300 | 0.7689 |
| 11:40 ET | 100 | 0.7689 |
| 11:42 ET | 900 | 0.7689 |
| 11:45 ET | 700 | 0.7689 |
| 11:47 ET | 9021 | 0.7662 |
| 11:49 ET | 500 | 0.766 |
| 11:54 ET | 200 | 0.7652 |
| 11:58 ET | 800 | 0.76595 |
| 12:02 ET | 15417 | 0.7629 |
| 12:03 ET | 100 | 0.7632 |
| 12:07 ET | 100 | 0.7677 |
| 12:09 ET | 400 | 0.7629 |
| 12:12 ET | 1400 | 0.7615 |
| 12:18 ET | 1400 | 0.7615 |
| 12:20 ET | 1000 | 0.766304 |
| 12:21 ET | 4834 | 0.7614 |
| 12:23 ET | 4979 | 0.7607 |
| 12:25 ET | 100 | 0.7607 |
| 12:27 ET | 8309 | 0.7612 |
| 12:34 ET | 995 | 0.756 |
| 12:36 ET | 900 | 0.7584 |
| 12:38 ET | 100 | 0.7555 |
| 12:39 ET | 100 | 0.7613 |
| 12:41 ET | 1300 | 0.7585 |
| 12:43 ET | 100 | 0.75845 |
| 12:45 ET | 1635 | 0.75845 |
| 12:48 ET | 600 | 0.7585 |
| 12:52 ET | 1500 | 0.7556 |
| 12:57 ET | 1500 | 0.75845 |
| 12:59 ET | 374 | 0.7588 |
| 01:03 ET | 1000 | 0.7613 |
| 01:06 ET | 200 | 0.7613 |
| 01:08 ET | 5900 | 0.7613 |
| 01:10 ET | 59490 | 0.7647 |
| 01:15 ET | 1000 | 0.765 |
| 01:17 ET | 600 | 0.76795 |
| 01:19 ET | 100 | 0.7712 |
| 01:21 ET | 800 | 0.7712 |
| 01:24 ET | 600 | 0.7712 |
| 01:26 ET | 1300 | 0.7682 |
| 01:28 ET | 100 | 0.7682 |
| 01:30 ET | 1100 | 0.7712 |
| 01:33 ET | 790 | 0.7712 |
| 01:35 ET | 700 | 0.7712 |
| 01:37 ET | 1200 | 0.7707 |
| 01:39 ET | 48978 | 0.7777 |
| 01:42 ET | 43083 | 0.776 |
| 01:44 ET | 2456 | 0.774 |
| 01:46 ET | 1800 | 0.774 |
| 01:50 ET | 2900 | 0.7757 |
| 01:51 ET | 1700 | 0.7756 |
| 01:57 ET | 300 | 0.7779 |
| 02:00 ET | 300 | 0.7779 |
| 02:04 ET | 100 | 0.7779 |
| 02:06 ET | 200 | 0.7779 |
| 02:08 ET | 400 | 0.7779 |
| 02:11 ET | 200 | 0.7779 |
| 02:15 ET | 100 | 0.7779 |
| 02:18 ET | 100 | 0.7779 |
| 02:20 ET | 1342 | 0.7779 |
| 02:22 ET | 357 | 0.7779 |
| 02:24 ET | 300 | 0.7779 |
| 02:27 ET | 400 | 0.778 |
| 02:31 ET | 100 | 0.7779 |
| 02:33 ET | 3662 | 0.7765 |
| 02:36 ET | 300 | 0.7779 |
| 02:38 ET | 6175 | 0.7785 |
| 02:40 ET | 300 | 0.7813 |
| 02:42 ET | 500 | 0.79 |
| 02:44 ET | 100 | 0.784 |
| 02:45 ET | 200 | 0.789 |
| 02:47 ET | 538 | 0.7889 |
| 02:49 ET | 100 | 0.78415 |
| 02:51 ET | 600 | 0.7899 |
| 02:54 ET | 16900 | 0.798 |
| 02:56 ET | 714 | 0.798 |
| 02:58 ET | 752 | 0.7975 |
| 03:00 ET | 400 | 0.79825 |
| 03:02 ET | 48438 | 0.7865 |
| 03:03 ET | 12141 | 0.77885 |
| 03:07 ET | 900 | 0.7804 |
| 03:14 ET | 100 | 0.7805 |
| 03:18 ET | 200 | 0.7824 |
| 03:20 ET | 600 | 0.7849 |
| 03:21 ET | 600 | 0.7849 |
| 03:23 ET | 500 | 0.7849 |
| 03:25 ET | 5150 | 0.7849 |
| 03:30 ET | 200 | 0.78175 |
| 03:32 ET | 1183 | 0.7849 |
| 03:34 ET | 100 | 0.7848 |
| 03:38 ET | 904 | 0.7849 |
| 03:39 ET | 257 | 0.7815 |
| 03:41 ET | 970 | 0.7838 |
| 03:43 ET | 26588 | 0.7837 |
| 03:45 ET | 51913 | 0.775 |
| 03:48 ET | 2718 | 0.77495 |
| 03:50 ET | 15419 | 0.7765 |
| 03:52 ET | 1100 | 0.775 |
| 03:54 ET | 22297 | 0.7759 |
| 03:56 ET | 810 | 0.77545 |
| 03:57 ET | 7588 | 0.764 |
| 03:59 ET | 12722 | 0.7759 |
May 10, 2024
DJ Kezar Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 8:06AM ET on Friday May 10, 2024 by Dow Jones
8:06AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Kezar Life Sciences 1Q Loss/Shr 30c >KZR, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
May 6, 2024
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 4:05PM ET on Monday May 06, 2024 by Dow Jones
4:05PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 56.0M | -0.6x | --- |
Kronos Bio Inc | 62.5M | -0.5x | --- |
LAVA Therapeutics NV | 71.0M | -1.7x | --- |
BioLine RX Ltd | 51.5M | -0.7x | --- |
Jaguar Health Inc | 49.5M | -0.1x | --- |
Curis Inc | 62.0M | -1.2x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Senior Vice President - Research and Drug Discovery
- Neel Anand
- Senior Vice President - CMC and Supply Chain
- Kieron Wesson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $56.0M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.24 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 8.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
